| Autor: |
Bruce MG; Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging Zoonotic and Infectious Diseases,Centers for Disease Control and Prevention (CDC),Anchorage, Alaska,USA., Bruden DL; Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging Zoonotic and Infectious Diseases,Centers for Disease Control and Prevention (CDC),Anchorage, Alaska,USA., Morris JM; Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging Zoonotic and Infectious Diseases,Centers for Disease Control and Prevention (CDC),Anchorage, Alaska,USA., Reasonover AL; Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging Zoonotic and Infectious Diseases,Centers for Disease Control and Prevention (CDC),Anchorage, Alaska,USA., Sacco F; The Alaska Native Medical Center,Anchorage, Alaska,USA., Hurlburt D; Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging Zoonotic and Infectious Diseases,Centers for Disease Control and Prevention (CDC),Anchorage, Alaska,USA., Hennessy TW; Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging Zoonotic and Infectious Diseases,Centers for Disease Control and Prevention (CDC),Anchorage, Alaska,USA., Gove J; Liver Disease and Hepatitis Program, Division of Community Health Services,Alaska Native Tribal Health Consortium,Anchorage, Alaska,USA., Parkinson A; Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging Zoonotic and Infectious Diseases,Centers for Disease Control and Prevention (CDC),Anchorage, Alaska,USA., Sahagun G; Internal Medicine Associate Inc., Anchorage,Alaska,USA., Davis P; The Alaska Native Medical Center,Anchorage, Alaska,USA., Klejka J; Yukon Kuskokwim Health Corporation,Bethel, Alaska,USA., McMahon BJ; Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging Zoonotic and Infectious Diseases,Centers for Disease Control and Prevention (CDC),Anchorage, Alaska,USA. |
| Abstrakt: |
We performed a study to determine rates of reinfection in three groups followed for 2 years after successful treatment: American Indian/Alaska Native (AI/AN) persons living in urban (group 1) and rural (group 2) communities, and urban Alaska non-Native persons (group 3). We enrolled adults diagnosed with H. pylori infection based on a positive urea breath test (13C-UBT). After successful treatment was documented at 2 months, we tested each patient by 13C-UBT at 4, 6, 12 and 24 months. At each visit, participants were asked about medication use, illnesses and risk factors for reinfection. We followed 229 persons for 2 years or until they became reinfected. H. pylori reinfection occurred in 36 persons; cumulative reinfection rates were 14·5%, 22·1%, and 12·0% for groups 1, 2, and 3, respectively. Study participants who became reinfected were more likely to have peptic ulcer disease (P = 0·02), low education level (P = 0·04), or have a higher proportion of household members infected with H. pylori compared to participants who did not become reinfected (P = 0·03). Among all three groups, reinfection occurred at rates higher than those reported for other US populations (<5% at 2 years); rural AI/AN individuals appear to be at highest risk for reinfection. |
